{"id":223,"date":"2024-01-05T10:00:00","date_gmt":"2024-01-05T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=223"},"modified":"2025-09-07T04:46:24","modified_gmt":"2025-09-07T04:46:24","slug":"china-bd-2024-insilico-medicine-and-menarini-stemline-enters-a-512-million-usd-license-on-a-preclinical-kat6-inhibitor-men2312","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/223.html","title":{"rendered":"[China BD 2024] Insilico Medicine and Menarini (Stemline) enters a 512 million USD license on a \u00a0preclinical KAT6 inhibitor ISM5043 (MEN2312)\u00a0"},"content":{"rendered":"\n<p>Announced Date: 2024-01-04 (January 4, 2024)<\/p>\n\n\n\n<p>Asset Name: ISM5043 (MEN2312)\u00a0<\/p>\n\n\n\n<p>Licensor: InSilico Medicine (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Stemline Therapeutics, a subsidiary of the Menarini Group\uff08Italy\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small &nbsp;Molecule<\/p>\n\n\n\n<p>Asset Target: KAT6 inhibitor <\/p>\n\n\n\n<p>Potential Indication: hormone sensitive breast tumors and other cancers<\/p>\n\n\n\n<p>Current Stage: preclinical<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority: <\/p>\n\n\n\n<p>Menarini Group will be granted global rights to develop and commercialize the asset.&nbsp;<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of&nbsp; $12 million,<\/p>\n\n\n\n<p>Development, regulatory, and commercial milestone payments, total up to $500 million.<\/p>\n\n\n\n<p>Royalties up to double digits.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.menarini.com\/en-us\/news\/news-detail\/menarini-group-and-insilico-medicine-enter-global-exclusive-license-agreement-for-novel-kat6-inhibitor-for-potential-breast-cancer-treatment-and-other-oncology-indications.html\">Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Insilico Medicine&nbsp; \u82f1\u77fd\u667a\u80fd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-01-04 (January 4, 2024) Asset Name: ISM5043 (MEN2312)\u00a0 Licensor: InSilico Medicine (China) Licensee (Buyer): &hellip; <a title=\"[China BD 2024] Insilico Medicine and Menarini (Stemline) enters a 512 million USD license on a \u00a0preclinical KAT6 inhibitor ISM5043 (MEN2312)\u00a0\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/223.html\"><span class=\"screen-reader-text\">[China BD 2024] Insilico Medicine and Menarini (Stemline) enters a 512 million USD license on a \u00a0preclinical KAT6 inhibitor ISM5043 (MEN2312)\u00a0<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-223","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=223"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/223\/revisions"}],"predecessor-version":[{"id":227,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/223\/revisions\/227"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}